Drug Profile
Lobeglitazone/metformin - Chong Kun Dang
Alternative Names: CKD 395; Lobeglitazone sulfate/metformin hydrochloride - Chong Kun DangLatest Information Update: 28 Aug 2018
Price :
$50
*
At a glance
- Originator Chong Kun Dang
- Class Antihyperglycaemics; Biguanides; Piperidines; Small molecules; Thiazolidinediones
- Mechanism of Action AMP activated protein kinase stimulants; Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in South Korea (PO, Tablet)
- 01 Nov 2015 Chong Kun Dang Pharmaceutical completes a pharmacokinetics phase I trial in Healthy volunteers in South Korea (PO) (NCT02648854)
- 01 Oct 2015 Chong Kun Dang Pharmaceutical initiates a pharmacokinetics phase I trial in Healthy volunteers in South Korea (PO) (NCT02648854)